Brief: Resonance Health Expects FY26 Underlying EBITDA A$2.6 Mln
05/05/2026 02:34
May 5 (Reuters) - Resonance Health Ltd RHT.AX: EXPECTS FY26 UNDERLYING EBITDA OF A$2.6 MILLION, UP 30% FROM PRIOR GUIDANCE UPDATES FY26 REVENUE GUIDANCE TO A$16.0 MILLION FROM A$17.0 MILLION Further company coverage: RHT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resonance Health
See all newsAustralia's Resonance Health jumps on FY26 forecast hike
Brief: Resonance Health Expects FY26 Underlying EBITDA A$2.6 Mln
Brief: Resonance Health Says Martin Blake Retires As Chair
Brief: Resonance Health Contracted For Clinical Drug Trial Worth A$13.775 Mln
Brief: Resonance Seeks Trading Halt Pending Announcement On Execution Of Contract For Services For Clinical Trial By Pharma Co